Abstract: Several gastrointestinal surgery procedures are effective as treatments for metabolic disorders such as obesity and diabetes. Minimally invasive procedures including intra-luminal gastrointestinal implants have been proposed to mimic the anatomical, physiological and metabolic changes achieved by these procedures. Many of these designs include long sleeve like elements that prevent contact of food with the walls of the small intestine. It is desirable to have simple delivery systems that can place these implants under endoscopic guidance. However, in order to anchor these sleeve elements safely and reliably, the inventors have previously disclosed anchoring means that anchor the sleeves at the junctions of the stomach and the intestine or the stomach and esophagus.

Abstract: The invention provides novel inhibitors or inactivators of protein arginine deiminase 1, pharmaceutical compositions and methods of use thereof. The invention also relates to molecular probes based on such compounds and methods of use thereof.

Abstract: The invention provides novel inhibitors or inactivators of protein arginine deiminases, pharmaceutical compositions and methods of use thereof. The invention also relates to molecular probes based on such compounds and methods of use thereof.

Abstract: The invention provides novel inhibitors or inactivators of protein arginine deiminases, pharmaceutical compositions and methods of use thereof. The invention also relates to molecular probes based on such compounds and methods of use thereof.

Abstract: The invention provides novel inhibitors or inactivators of protein arginine deiminases, pharmaceutical compositions and methods of use thereof. The invention also relates to molecular probes based on such compounds and methods of use thereof.

Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.

Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.

Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.

Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.

Abstract: In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes Cys-Val-Val-Val-Val-Val-Val-Lys-Lys conjugated with a synthetic polymer and has a diameter of from about 50 nm to about 150 nm.

Abstract: In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead.

Abstract: In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead.

Abstract: Methods for diagnosing disease that is characterized by an overabundance of citrullinated proteins such as colitis, rheumatoid arthritis, and/or malignant cancer in a subject are provided. The PAD protein activity level can be measured in a tissue sample (e.g., serum) of the subject and then compared to a control PAD protein activity range of a control group. A finding of an increased PAD protein activity level in the tissue sample of the subject compared to the PAD protein activity level of the control group is indicative of disease characterized by an overabundance of citrullinated proteins in the subject.

Abstract: In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes Cys-Val-Val-Val-Val-Val-Val-Lys-Lys conjugated with a synthetic polymer and has a diameter of from about 50 nm to about 150 nm.

Abstract: Computer-implemented systems and methods for managing information include one or more client terminal devices in communication with a data interchange system. In one instance, the data interchange system may facilitate communication between a device manufacturer and a clinical site. One or more of the client terminals devices may be configured to: (a) collect the medical device information from the medical device; (b) transmit the medical device information to the medical device manufacturer and/or the clinical site via the interchange system; and (c) receive information from the medical device manufacturer and/or the clinical site via the interchange system. The client terminal device may be further configured to: (d) activate, deactivate or configure a medical device.

Abstract: Computer-implemented systems, apparatus and methods for managing information, operations and functions in a complex medical environment and providing a command control center interface for receiving/sending/displaying data, relating to products, instructions, diagnosis, consultation, patient's information, supplies and their provision, registration, scheduling, updating and like operational functions and features, and updating on an ongoing basis to coordinate, control and synchronize necessary and/or desirable operations within the environment, whereby the “hospital of the future” is effectively facilitated with proficiency and efficiency in an accurate and reliable manner. Such systems may also include one or more client terminal devices in communication with a data interchange subsystem.

Abstract: In accordance with one embodiment of the present disclosure, a method to identify a protein arginine deiminase 4 inhibitor is disclosed. The method includes performing a competitive assay in which a potential inhibitor compound competes with rhodamine-conjugated fluoroamidine to bind to protein arginine deiminase 4. Fluorescence is measured to determine an estimate of the amount of fluorescent protein arginine deiminase 4 that is present in the assay.

Abstract: In an example embodiment, workflow based procedures are authored, tested and converted to a collection of resource automation scripts with orchestration rules. The scripts and rules are uploaded to a cloud-based provisioning service. The cloud-based provisioning service follows the orchestration rules to coordinate with a provisioning agent installed on a VM host, storage area network (SAN) or other network device to execute a sequence of scripts to provision or tear down resources.

Abstract: In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead.

Abstract: Peptide-based borono-lectin sensors, along with their synthesis and analysis and methods of use, are generally described. These sensors use peptides as a scaffold and introduce boronic acid moieties onto the peptide scaffold as the binding site for the targeted analyte (e.g., carbohydrates, glycans, etc.). The boronic acid moieties can be arranged on the protein scaffold in such a manner that a particularly targeted carbohydrate or glycoprotein will bond to the protein scaffold via the boronic acid functionality. Such bonding can indicated the presence or absence of that targeted analyte in the sample.